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4ABSTRACT
Lynch syndrome is the most prevalent cancer predisposition syndrome that causes
significantly increased lifetime risk of cancer in multiple organs such as colorectum,
endometrium and ovarium. The predisposition is caused by germline mutations in DNA
mismatch repair (MRR) genes MLH1, MSH2, MSH6, and PMS2. Lynch-like syndrome
colorectal tumors, like Lynch syndrome tumors, are MMR-deficient. Nevertheless,
Lynch-like syndrome tumors do not bear germline mutations in MMR genes nor
methylation of the promoter regions of MMR genes that would explain the deficiency.
Instead, MMR deficiency in majority of Lynch-like syndrome tumors is caused by two
somatic mutations in the MMR genes. Dysfunctional MMR protein complex enables
accumulation of mutations in the genome (mutator phenotype) and, eventually,
microsatellite instability and cancer.
The reasons behind organ selectivity in MMR-deficient tumors are unknown, and
whether breast cancer is part of the Lynch syndrome spectrum is under debate. The
germline mutations in MMR genes are well studied, but molecular characteristics of
Lynch syndrome tumors remain to be studied further. Lynch-like syndrome tumors
remain less well characterized: besides the double somatic MMR mutations as a cause
of MMR deficiency, their molecular and clinicopathological features as well as their
incidence in the population remain poorly known. Currently, the only possibility to
diagnose Lynch-like syndrome is by ruling out the possibility of germline mutations in
MMR genes (Lynch syndrome) or methylation of the promoter regions of MMR genes.
Synchronous ovarian and endometrial carcinomas are common in Lynch syndrome;
whether they are of same origin (metastatic cancer) or two independently developed
primary cancers remains to be resolved. We aimed to characterize the epigenetic and
somatic mutation profiles in Lynch syndrome representing colorectal, ovarian,
endometrial and breast carcinomas, and to identify new unique features that could be
used in evaluating cancer risk, diagnosis and targeted treatment.
We used targeted high-throughput sequencing of 578 known cancer genes to investigate
the somatic mutation profiles, and methylation-specific multiplex ligation-dependent
5probe amplification to study the epigenetic profiles of the tumors. Non-synonymous
somatic mutations were detected from sequencing data of the paired tumor and normal
tissues to determine mutation signatures and identify potential driver genes. The data
was also compared statistically between tumors of different origin, epigenetic status, and
between breast carcinomas from Lynch syndrome mutation carriers and their known
non-carrier family members.
We observed that Lynch- and Lynch-like syndrome tumors have unique somatic
mutation and methylation profiles. We were able to link the methylator phenotype to
high somatic mutation rates, and Lynch-like colorectal tumors to hypermethylated CpG
island methylator phenotype (CIMP), which are novel findings. Our discovery of high
mutation burden in genes associated with epigenetic regulation provides a new link
between genetic and epigenetic factors in tumorigenesis. Genetic and epigenetic
characterization of synchronous ovarian and endometrial carcinomas indicated shared
origin, in analogy to sporadic cases. Molecular characteristics and especially mutational
signatures of breast tumors of Lynch syndrome mutation carriers indicated that breast
carcinoma is likely to be part of the Lynch syndrome tumor spectrum.
These findings bear potential clinical relevance since the molecular tumor profiles may
be used in diagnosis and may guide tailored management of the patients. Many of the
mutated genes are part of signaling routes to which targeted molecules either exist or can
be developed.
Keywords: Lynch syndrome, Lynch-like syndrome, panel sequencing, epigenetics,
somatic mutation profile, promoter methylation, colorectal cancer, ovarian cancer, breast
cancer
6TIIVISTELMÄ
Lynchin syndrooma on yleisin syövälle altistava perinnöllinen syndrooma, joka lisää
muun muassa suolisto-, kohtu- ja munasarjasyövän riskiä. Alttiuden aiheuttavat
perinnölliset mutaatiot DNA:n emäspariutumisvirheitä korjaavissa (engl. DNA
mismatch repair, MMR) geeneissä MLH1, MSH2, MSH6, and PMS2. MMR-
proteiineista koostuvan koneiston puutteellinen toiminta johtaa mutaatioiden
kertymiseen genomiin ja lopulta mikrosatelliitti-epätasapainoon ja syövän syntyyn.
Lynchin kaltaisen (engl. Lynch-like) syndrooman suolistokasvainten MMR-proteiinien
puutos ei selity ituratamutaatioilla tai MMR-geenien promoottorialueiden
hypermetylaatiolla. Tiedetään, että valtaosassa tapauksista Lynch-like -kasvainten
MMR-geenien normaali toiminta on hiljentynyt kahden somaattisen eli hankitun
mutaation seurauksena.
Kudosspesifisyyden syitä syövissä, joissa MMR-koneiston toiminta on puutteellista, ei
vielä tunneta. Rintasyövän kuulumisesta Lynchin syndrooman syöpäspektriin on
ristiriitaisia tutkimustuloksia, ja synkronisten munasarja- ja kohdunrungonsyövän
alkuperästä (metastasoitunut kasvain vai itsenäisesti kehittyneet primaarikasvaimet) ei
löydy julkaistua tutkimustietoa. MMR-geenien perinnölliset mutaatiot tunnetaan jo
melko hyvin, mutta Lynchin syndrooman kasvainten muista molekulaarisista
ominaisuuksista tarvitaan vielä lisää tutkimustietoa. Lynch-like -kasvaimista on
niukemmin tutkimustietoa: kahden somaattisen MMR-mutaation lisäksi niiden
molekulaarisista ja kliinispatologisista ominaisuuksista sekä kyseisen tautimuodon
esiintyvyydestä populaatiotasolla tiedetään hyvin vähän. Toistaiseksi Lynch-like -
syndrooma on mahdollista diagnosoida vain poissulkemalla Lynchin syndrooma ja
MMR-geenien hypermetylaatio. Tavoitteenamme oli kartoittaa Lynchin ja Lynch-like -
syndroomaan kuuluvien suolisto-, munasarja-, kohdunrungon ja rintasyöpien
somaattisia ja epigeneettisiä muutoksia. Näiden piirteiden tunnistaminen eri
syöpätyypeissä mahdollistaisi syövän riskin arvioinnin, tarkemman diagnosoinnin sekä
kohdennetun hoidon kehittämisen.
Tutkimme somaattisia mutaatioita sekvensoimalla kasvainten DNA:ta paneelilla, joka
kattaa 578 tunnettua syöpägeeniä, sekä niiden metylaatioprofiilia ns. MS-MLPA (eng.
7methylation-specific multiplex ligation-dependent probe amplification) -tekniikan
avulla. Tunnistimme ei-synonyymiset mutaatiot parittaisesta kasvain- ja
normaalikudosten sekvenssidatasta määrittääksemme mutaatioprofiilit sekä
syövänkehityksen ajurigeenit (engl. driver genes). Tilastolliset vertailut tehtiin eri
kudosten ja metylaatiostatusten kesken. Lisäksi Lynchin syndrooman
mutaationkantajilta peräisin olevia rintasyöpiä verrattiin rintasyöpiin sukulaisilta, jotka
eivät olleet perineet sukunsa alttiusmutaatiota.
Havaitsimme, että Lynchin ja Lynch-like syndroomien syövillä on niille
luonteenomaiset epigeneettiset ja somaattiset mutaatioprofiilit. Uusina löydöksinä
osoitimme yhteyden yleistyneen hypermetylaatio- ja mutaatiotaipumuksen välillä, sekä
yhteyden Lynch-like -kasvainten ja hypermetyloituneen fenotyypin välillä.
Epigeneettiseen säätelyyn osallistuvien geenien sekä DNA:n korjausgeenien lisääntynyt
mutaatioherkkyys liittää geneettiset ja epigeneettiset tekijät uudella tavalla toisiinsa
syövänkehityksessä. Se, että synkroniset munasarjan ja kohdunrungon kasvaimet olivat
geneettisesti ja epigeneettisesti yhteneväisiä, osoittaa, että kasvaimet ovat samaa
alkuperää, eli edustavat metastasoitunutta kasvainta, kuten vastaavissa sporadisissa
syövissä on aiemmin osoitettu. Lynchin syndrooman kantajien ja ei-kantajien
rintasyöpien molekulaariset tutkimukset ja erityisesti mutaatioprofiilit toivat viitteitä
siitä, että rintasyöpä kuuluu Lynchin syndrooman kasvainspektriin.
Tutkimus tuo tärkeää uutta tietoa Lynchin ja Lynch-like syndrooman syöpien
syntymekanismeista sekä ominaispiirteistä, joita on mahdollista hyödyntää syövän
diagnosoinnissa sekä kohdennettua hoitoa suunniteltaessa. Monet mutatoituneista
geeneistä kuuluvat säätelyreitteihin, joihin on joko olemassa tai kehitettävissä
kohdennettuja lääkemolekyylejä.
Avainsanat: Lynchin syndrooma, Lynch-like syndrooma, paneelisekvensointi,
promoottorin metylaatio, somaattinen mutaatioprofiili, epigenetiikka, suolistosyöpä,
munasarjasyöpä, rintasyöpä
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INTRODUCTION
Cancer is one of the leading causes of morbidity and the second leading cause of death
globally. Regardless of the extensive effort and money spent on research, cancer was
reported to be the cause of death in 9.6 million cases in 2018. However, over 50% of the
patients diagnosed with cancer in Finland are currently cured (Cancer Society of Finland,
All about Cancer). Environmental factors such as UV-radiation, tobacco smoke and
Western style diet are known risk factors for many cancers. Evolving diagnostic methods
and the fact that people tend to live longer may also increase the incidence of diagnosed
cancers.
Cancer is a group of distinct diseases caused by genetic and epigenetic changes, affecting
nearly all the organs and cell types in the human body. Genetics is defined as information
coded in the DNA sequence, whereas epigenetics refers to inherited patterns of gene
expression (Esteller and Herman, 2002). These changes disrupt  normal function of the
cell allowing uncontrolled cell proliferation and metastasis into distant tissues and
organs (Stratton et al., 2009).
Every cell in a human body carries a single genome coded into two sets of chromosomes
present in the fertilized egg. In addition to the environmental carcinogens, normal cells
acquire somatic mutations in a steady rate caused internal mutagenic agents (eg. radical
oxygen species caused by normal metabolic functions) and by errors occurring during
DNA replication (Stratton et al., 2009). DNA repair machinery of a normal cell repairs
most of these damages. In some cancers, the acquisition rate of somatic mutations may
be increased by for example deficiencies in DNA mismatch repair (MMR) machinery
which causes accumulation of somatic mutations in the genome that may eventually lead
to cancer (Jeggo et al., 2016). These cancer-promoting mutations can also be germline
mutations which are inherited from the parents.
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Lynch syndrome (LS) is the most common cancer predisposition syndrome in the world
(Win et al., 2017). It is an autosomal dominant disorder caused by germline mutations
in one of the DNA mismatch repair (MRR) genes MLH1, MSH2, MSH6, and PMS2
(Peltomäki, 2005). Dysfunction of MMR machinery leads to microsatellite instability
(MSI) that is characteristic to majority of LS tumors, whereas less common in sporadic
tumors (Lotsari et al., 2012, Peltomäki, 2003). MMR genes comply with the Knudson’s
two-hit mechanism: the first hit causes cancer predisposition and the second commences
tumorigenesis (Knudson, 1971).
The revised Bethesda guidelines determines colorectal, endometrial, stomach, ovarian,
ureter, renal pelvis, brain, small bowel, and hepatobiliary tract cancers as part of the LS
tumor spectrum, due to the increased relative risk compared to general population, and
the generally lower age of onset (Umar et al., 2004). Debate is ongoing whether breast
cancer is part of LS tumor spectrum. Breast cancer is the most common cancer in women
worldwide, but guidelines recommending increased breast cancer screening for women
with LS are currently lacking.
Besides the germline mutations in MMR genes, little is known about the somatic
mutational profiles or epigenetic profiles of the LS tumors, or the reasons for organ
selectivity in germline mutation carriers. Only recently, Lynch-like syndrome (LLS) was
established as a consistent group of MMR-deficient tumors by identification of double
somatic mutations as the mechanism associated with majority of the cases
(approximately up to 70%) (Pearlman et al., 2019). The mechanisms explaining the
remaining cases, and the somatic and epigenetic profiles, are nevertheless, unknown.
Because Lynch syndrome is a well-established cancer syndrome, it provides a good
model for both LS tumors and carcinogenesis in general. It serves as a valuable model
to investigate the multistep tumorigenesis of colon and other organs: every cell of a LS
mutation carrier bears the strong predisposing defect, but the tumor development
requires an additional hit to occur in a target tissue. Discovering new unique somatic
Introduction 15
features of LS and LLS tumors could enhance diagnostics and targeted treatment of these
tumors.
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REVIEW OF THE LITERATURE
1. Cancer in Finland
In 2017, almost 35 000 people were diagnosed with cancer in Finland, and the numbers
are rising as they have been for over 60 years (tracked time) (Finnish Cancer registry).
Two thirds of the diagnosed patients are cured (Cancer Society of Finland, All about
Cancer). In Finland, the most common cancers in women are breast, colorectal and lung
cancer, and prostate, colorectal and lung cancer in men (Table 1). Almost 2.1 million
people worldwide develop breast cancer every year, being the second most common
cancer in the world, and in Finland nearly 5000 new cases are diagnosed annually
(Finnish Cancer registry, International Agency for Research on Cancer). Prostate cancer
is the world’s fourth most common cancer with nearly 1.3 million new diagnoses every
year (International Agency for Research on Cancer), whereas it is the most common
cancer in males in Finland (Table 1) (International Agency for Research on Cancer).
Colorectal cancer is common in Western populations (Dermadi et al., 2014). It is the
second most common cancer in both males and females in Finland with over 3000 new
cases diagnosed annually (Finnish Cancer registry). Lung cancer is the third most
common cancer in Finland in both women and men, but it is the most common cancer
in the world with nearly 2.1 million new cases annually (Table 1 (International Agency
for Research on Cancer)). Ovarian cancer is less common in Finland, with only 442
patients diagnosed in 2017, and the incidence during the last ~30 years has remained
somewhat even, unlike in many other cancers (Finnish Cancer registry).
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Table 1. Statistics of cancer in Finland
Female
# Tissue New cases Deaths Incidence* Relative survival rate**
1. Breast 4947 923 167.18 91 %
2. Colorectal 1575 650 49.29 67 %
3. Lung 999 780 31.61 19 %
…
Ovary 442 315 14.51 42 %
Male
# Tissue New cases Deaths Incidence* Relative survival rate**
1. Prostate 5444 912 212.05 92 %
2. Colorectal 1784 718 70.49 64 %
3. Lung 1712 1502 67.11 12 %
*Relative per 100 000, age adjusted (Finland 2014)
**Relative percentage of the patients living five years after diagnosis (Surveillance period
2015-2017). Age adjusted.
This data is based on the Finnish Cancer Registry (Finnish Cancer Registry)
2. Hallmarks of cancer
Cancer is a genetic and epigenetic disease encompassing a group of distinct diseases
emerging from almost all organs and cell types in the human body. This group of
diseases is characterized by uncontrolled cell proliferation and metastasis, allowing cells
to break through the tissue boundaries and invade to distant tissues and organs (Esteller
and Herman, 2002, Stratton et al., 2009). The evolution of a normal cell into a cancerous
cell occurs by multiple changes in DNA sequence, chromosome rearrangements and
aneuploidy, leading to genome instability. This enables cells to sustain proliferative
signaling, evade growth suppression, resist controlled cell death (apoptosis), induce
angiogenesis, activate invasion and metastasis, and acquire replicative immortality.
These biological capacities are known as hallmarks of cancer (Hanahan and Weinberg,
2000). Two additional emerging hallmarks have been discovered: reprogramming of
energy metabolism and evading immune destruction. In addition, the complexity and
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impact of tumor microenvironment was acknowledged as contributor of hallmark traits
and, hence, tumorigenesis (Hanahan and Weinberg, 2011).
3. Genetics of tumorigenesis
Cancer develops through Darwinian natural selection: mutations enable adaptation to the
changes in the surrounding microenvironment. Deleterious mutations may be excluded,
whereas certain mutations may offer the cell an advantage to proliferate and survive
more efficiently. The latter, however, occasionally results into development of cancer
when the advantageous mutations allow a single cell to escape controlled cell
proliferation and eventually metastasize (Stratton et al., 2009).
Every cell in the human body carries a diploid genome of the fertilized egg. On top of
the germline mutations that are inherited from the parents, normal cells acquire
mutations on a steady rate by external and internal mutagenic agents as well as errors
occurring during the intrinsic DNA replication. These acquired mutations, called somatic
mutations, differ cells from the progenitor fertilized egg and their parental cells, and are
passed on to the daughter cells (Stratton et al., 2009). Tobacco smoke and ultraviolet
radiation are examples of external carcinogens, whereas radical oxygen species from
normal metabolic functions are classified as intrinsic mutation causing factors (Stratton
et al., 2009). DNA repair machinery of a normal cell repairs most of these damages. The
acquisition rate of somatic mutation may be increased in some cancers for example due
to deficiencies in DNA mismatch repair (MMR) genes. This causes accumulation of
single nucleotide changes and small insertions and deletions in the genome, causing a
‘mutator phenotype’ and, eventually, leading to MSI and cancer (Jeggo et al., 2016).
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3.1 Driver and passenger mutations
Somatic mutations are classified as driver and passenger mutations according to their
contribution to tumorigenesis. Driver mutations occur in cancer genes (Catalogue of
somatic mutations in cancer (COSMIC)) that, according to their name, drive cancer
development enabling growth advantage over the normal cells. Driver mutations are
therefore positively selected during the course of cancer evolution (Stratton et al., 2009).
Mutations not promoting cancer development are termed passenger mutations. They can
occur relatively randomly around the genome and their effect on normal gene function
may be neutral. Passenger mutations likely exist in an ancestor of a cancer cell solely by
chance at the time the cell acquires a driver mutation turning it into a cancerous cell,
without contributing to tumorigenesis (Vogelstein et al., 2013).
3.2 Oncogenes and tumor suppressor genes
Cancer-associated genes are typically classified as oncogenes and tumor suppressor
genes. A normal form of an oncogene is called proto-oncogene which acts in important
cellular functions such as cell growth, proliferation, cell survival and apoptosis (Croce,
2008). When aberrantly activated by for example a mutation, proto-oncogene is
transferred into an active oncogene, which promotes growth and hence participates in
driving tumorigenesis (Vogelstein et al., 2013). Tumor suppressor genes, contradictory
to oncogenes, gain their tumor-promoting potential through inactivation of gene function
(Vogelstein et al., 2013). In normal cells, they bear growth limiting potential and act as
gatekeepers and caretakers by controlling cell division, DNA damage repair and
apoptosis. Inactivation by mutation enables uncontrolled cell division, deficient DNA
repair leading to accumulation of errors in the genome, and insufficient apoptosis (Sun
and Yang, 2010). Mutations in oncogenes genes are typically dominant in their effect.
In other words, one mutated allele of the gene is sufficient to promote carcinogenesis.
(Stratton et al., 2009). Mutations in tumor suppressor genes, however, are usually
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recessive in their effect on cellular level. This means that one normal allele is sufficient
to retain normal control of cellular functions, and thus follows the Knudson two-hit
hypothesis. According to Knudson two-hit hypothesis (Knudson, 1971) two mutations,
genetic hits, are required to inactivate the gene in question. When one defective allele
has been inherited in germline, only one somatic hit is required for inactivation and hence
the carrier individuals tend to develop the disease at a younger age. Majority of cancer
promoting genes are tumor suppressor genes, in which mutations cause defective
proteins resulting in tumorigenesis (Rahman, 2014).
3.3 Genomic instability
Genomic instability is a common feature in human cancers that drives tumorigenesis by
generating heterogeneity within the tumor cells inside the tumor (Andor et al., 2016).
This intratumor heterogeneity provides genetic diversity against natural selection,
enabling a tumor to efficiently adapt and survive. Chromosomal instability (CIN), a form
of genomic instability, is a frequent feature of sporadic cancer but the mechanisms
behind it remain to be studied further (Armaghany et al., 2012). CIN is a hallmark of
tumors that evolve through the classical pathway, in which oncogenes such as KRAS and
tumor suppressor genes such as APC or TP53 are affected (Fearon and Vogelstein,
1990). Alterations associated with CIN are large-scale chromosomal rearrangements
such as deletions, duplications, translocations, amplifications, insertions of transposable
elements, or even aneuploidy (gain or loss of entire chromosomes) (Pino and Chung,
2010). MSI, another form of genomic instability, is characterized as variation in lengths
of repeated microsatellites (small insertions and deletions) due to errors in DNA
replication (Boland et al., 1998). Microsatellites are short nucleotide repeats scattered
throughout the genome, often located in non-coding regions. The length of the repeats is
unique in each individual (Jeffreys et al., 1992, Li et al., 2002). MSI results from
deficient DNA repair leading to accumulation of mutations in the genome (mutator
phenotype) which drives malignant transformation (Loeb, 1991). MSI is, hence, a
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hallmark of cancers, in which DNA repair mutations are inherited (Lynch syndrome),
but it is also detected in a proportion of different sporadic cancers including colorectal,
gastric, endometrial, and ovarian (endometrioid) tumors. In sporadic cases MSI is
associated with silenced expression of MLH1 by promoter methylation (Imai and
Yamamoto, 2008, Vasen et al., 2015).
3.4 POLD1 and POLE mutations
Alternative mechanism for mutator phenotype are mutations in the genes POLD1 and
POLE encoding for DNA proofreading enzymes, resulting in increased number of base
substitutions (Jansen et al., 2016, Palles et al., 2013). Hypermutability by POLD1 and
POLE mutations are observed in colorectal (Elsayed et al., 2015, Valle et al., 2014),
endometrial (Church et al., 2015), and breast cancers (Voutsadakis, 2019).
4. Epigenetics of tumorigenesis
Epigenetic changes refer to inherited changes in gene expression without changes in the
primary DNA sequence, that are thus potentially reversible (Feinberg and Tycko, 2004).
In normal cells, epigenetic mechanisms are rigorous mechanisms for regulating
homeostasis of gene expression in the cells (Esteller and Herman, 2002). Forms of
epigenetic modifications consist of histone modifications, non-coding RNA expression
(micro-ribonucleic acid, miRNA), modifications of chromatin remodeling system, and
DNA methylation (Peltomäki, 2012). The latter is a common form of epigenetic change
observed in cancer. DNA methylation mainly appears as modification of cytosine
residues in CpG dinucleotides in CpG-rich regions called CpG islands mainly located in
gene promoters (Sharma et al., 2010). Elevated DNA methylation (hypermethylation) in
the promoter region can inhibit function of tumor suppressor genes, facilitating cancer
development. However, decreased methylation (hypomethylation) in the promoter
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regions of tumor promoting oncogenes may forward tumorigenesis (Baylin et al., 1986,
Cross and Bird, 1995, Feinberg and Tycko, 2004) (Figure 1). For example, the
methylation of the promoter region of MLHI is a common mechanism associated with
the loss of MLH1 gene expression, associated with a proportion of MSI tumors.
Promising new therapies have been developed to target the heritable but reversible nature
of epigenetic changes, which provide a platform for future treatments (Qi et al., 2016).
CpG island DNA methylation is also an important regulatory element during embryonic
development, for example by playing a role in X-chromosome inactivation and gene
imprinting (Jones, 2012).
Figure 1. DNA methylation in cancer. The promoter hypermethylation (black circles,
upper row) is a common mechanism for silencing tumor suppressor gene expression in
cancer.  Hypomethylation (white circles, lower row) of silenced oncogenes leads to gene
activation. Green arrow indicates normally expressed gene, pointed green arrow
indicates low gene expression, and red arrow with x indicates loss of gene expression.
Modified from Peltomäki 2012 (Peltomäki, 2012).
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5. Inherited cancer predisposition
Some individuals may have an inherited (germline) mutations predisposing to cancer
development. Cancer itself is not contagious and it cannot be inherited from the parent,
but the predisposition to cancer development can be inherited, which results in the lower
age of onset. Heritability refers to the fraction of phenotypic variability attributable to
genetic factors and ranges from 0% (all variability is due to environmental factors) to
100% (all variability is due to genetic factors). A large classical twin study conducted in
the Nordic countries estimated that familial cumulative cancer risk was 32% and overall
heritability 33% (Mucci et al., 2016). Significant heritability was observed in skin
melanoma (58%), prostate cancer (57%), non-melanoma skin cancer (43%), ovarian
cancer (39%), renal cancer (38%), breast cancer (31%), and cancer of corpus uteri (27%)
(Mucci et al., 2016). In addition, heritability of 14% and 15% was observed in colon
cancer and rectal and anal cancer, respectively (Mucci et al., 2016). A recent large
genome-wide association study across six common cancers (breast, colorectal, head and
neck, lung, ovarian and prostate cancers) indicated that common germline genetic
mechanisms affect the development of solid tumors in different tissues (Jiang et al.,
2019). Their single nucleotide polymorphism (SNP) heritability analysis estimated the
following heritability values: approximately 12-17% for breast cancer, 7-12% for
colorectal cancer, 5-15% for head and neck cancer, 6-10% for lung cancer, 2-5% for
ovarian cancer, and 14-23% for prostate cancer (Jiang et al., 2019). These heritability
values represent the familial aspect of cancer, indicating that more tissue-specific tumors
arose within the families that would be expected by chance alone. However, heritability
does not explain the reasons behind the phenomenon.
More than 110 genes have been discovered that are associated with hereditary cancer
syndromes, of which the most common occur in genes involved in DNA repair (Rahman,
2014, Romero-Laorden and Castro, 2017). Reportedly, 2–8% of all colorectal cancers
and 20% of colorectal cancers diagnosed before the age of 50 years are due to pathogenic
germline variants in high risk cancer genes (AlDubayan et al., 2018, DeRycke et al.,
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2013, Mork et al., 2015, Pearlman et al., 2017, Stoffel et al., 2018, Yurgelun et al., 2015).
Classification of familial colorectal cancer syndromes are represented in Figure 2. Of
ovarian cancers, as many as 18-26% represent a germline mutations in a cancer
susceptibility gene (Hauke et al., 2019, Norquist et al., 2016, Toss et al., 2015), whereas
in breast cancer the estimate is only 5-10% (Couch et al., 2014). These represent the
hereditary form of cancer, since the underlying causative mechanism is known and is
attributable to a single susceptibility gene with high-penetrance.
Figure 2. Familial colorectal cancer syndromes. Familial colorectal cancer syndromes
are divided into polyposis syndromes (left) and non-polyposis syndromes (right). Lynch
syndrome and Lynch-like syndrome are forms of non-polyposis syndromes, but Lynch-
like syndrome is not hereditary and is hence represented in dashed line. Polymerase
proofreading-associated polyposis (in the middle) is not categorized to either of the two
categories. Based on information in Valle et al. (Valle et al., 2019).
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5.1 Lynch syndrome
Lynch syndrome (LS) is the most common cancer predisposition syndrome and it is
known to increase the risk of colorectal cancer and other epithelial malignancies, such
as ovarian, endometrial, gastric, urinary tract and bladder, kidney, small bowel, and
hepatobiliary tract tumors (Samadder et al., 2017, Watson and Riley, 2005). In addition,
other cancers such as pancreatic and brain tumors occur more often in LS patients
compared to average population (Lynch and de la Chapelle, 2003, Watson et al., 2008)
(see Figure 3). Debate is ongoing on whether breast cancer is part of LS tumor spectrum
(Aarnio et al., 1999, Buerki et al., 2012, Lotsari et al., 2012, Pande et al., 2012, Saita et
al., 2018, Watson et al., 2008, Win et al., 2012). However, the reasons for organ
selectivity in germline mutation carriers are unknown. Even though the incidence of an
affected individual to develop cancer is high (75% in females and 58% in men before
the age 70), the rate of survival in most cancers is higher compared to sporadic cancers
(Moller et al., 2017b).
Up to 54% of female LS mutation carriers develop endometrial cancer and 24% ovarian
cancer during their lifetime, making endometrial cancer as or even more prevalent cancer
as CRC in female LS mutation carriers (Bonadona et al., 2011, Moller et al., 2017a). The
histology of endometrial carcinomas in majority of LS cases is endometrioid (90%)
(Rossi et al., 2017), whereas majority of epithelial ovarian carcinomas in LS are non-
serous (77%) (Helder-Woolderink et al., 2016). Endometrial and ovarian carcinomas are
diagnosed simultaneously in 10% of sporadic cases (Kelemen et al., 2017), in which
recent studies indicate shared origin of the synchronous tumors (metastatic disease)
(Anglesio et al., 2016, Schultheis et al., 2016). In LS, endometrial and ovarian
carcinomas are diagnosed simultaneously in 20% of the cases (Rossi et al., 2017, Ryan
et al., 2017). However, shared vs. independent origin of synchronous endometrial and
ovarian carcinomas occurring in LS is unknown.
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Figure 3. Cancer in Lynch syndrome. Average risk of different cancers in LS mutation
carrier is calculated based on the risk reported per MLH1, MSH2, and MSH6 (individual
risks in parenthesis after average risk, respectively). Risk for breast, ovarian, and
endometrial cancers are calculated in women only. The data is based on MØller et al.
(Moller et al., 2018).
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LS results from germline mutations in MMR genes MLH1, MSH2, MSH6, and PMS2
(Thompson et al., 2014). Deletions in EPCAM associated with epigenetic silencing of
MSH2 are also linked to LS, but they are relatively rare. These truncating 3’ end deletions
cause epigenetic silencing of the neighbor MSH2 gene in tissues in which EPCAM is
expressed (Kuiper et al., 2011). An individual carrying a germline mutation in one of the
MMR genes has a 50% risk to pass it to a child, representing the dominant characteristics
of LS predisposing mutations. Extremely rare cases of constitutional MMR deficiency
(CMMRD), severe form of childhood cancer syndrome, have been reported, in which a
child inherits a defective MMR allele from both parents causing cancer already in early
childhood (Wimmer et al., 2014). Numerous studies have been conducted regarding the
germline mutations in MMR genes, but little is known about the somatic mutational
profiles or epigenetic status of the LS tumors.
MMR proteins form a DNA repair complex that repairs mismatched bases and
insertion/deletion loops in DNA that result from environmental factors or cellular
processes, or that occur naturally during DNA replication (Liu et al., 2017) (Figure 4).
Defects in MMR machinery cause accumulation of replication errors in the genome
which can be detected as MSI, characteristic to most of the LS tumors (Peltomäki, 2001).
When MMR complex is defective, small mono- and dinucleotide deletions and insertions
accumulate in the genome leading to hypermutability and increased tumor heterogeneity
advantageous to tumorigenesis (Jeggo et al., 2016). Inactivation can be caused by
germline mutation in one of the four MMR genes combined with a second somatic hit
inactivating the normal allele (Aaltonen et al., 1998). Inactivation or second hit can also
be caused by hypermethylation of MLH1 promoter region, which is the case in sporadic
cancers (Jacob and Praz, 2002).
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Figure 4. DNA mismatch repair. Simplified presentation of DNA mismatch repair
pathway. 1. Mismatch recognition: Occurrence of single basepair mismatch in DNA
synthesis. 2. Recognition of mismatch bases occurs by a complex of MSH6 and MSH2
heterodimers that combined form a hMutSα complex, together with Proliferating cell
nuclear antigen (PCNA), both binding to mismatch site. MLH1 and PMS2 heterodimers
combined form a hMutLα complex that is recruited to the site after recognition. 3.
Together with exonuclease EXO1, hMutLα dissembles the mismatched DNA sequence.
4. DNA polymerase δ (DNA Pol δ) synthesizes a new complementary DNA strand,
which is ligated with the undamaged strand by DNA ligase I. 5. Newly repaired DNA
strand. Based on information in Liu et al. (Liu et al., 2017).
Before the genetic mechanisms of Lynch syndrome were established, Amsterdam
criteria (AC) and Bethesda guidelines (BG), their variations AC II and revised BG,
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together with the patient’s pedigree and family history of cancer were used to identify
families at risk for LS (Rodriguez-Bigas et al., 1997, Umar et al., 2004, Vasen et al.,
1991, Vasen et al., 1999). Peltomäki et al. (Peltomäki et al., 1993) discovered the first
susceptibility locus predisposing to LS, enabling genetic testing. MMR gene variants
and their estimated pathogenicity classifications are collected in the InSIGHT DNA
variant database (InSIGHT DNA Variant Database). Currently 320 Lynch syndrome
families and more than 1700 diagnosed individuals have been registered in the National
Lynch syndrome registry of Finland (LSRFi).
Identification of LS mutation carriers is important in order to offer access to regular
surveillance programs such as colonoscopy and gynecological screenings to enhance the
early detection of cancer and thus, increase the likelihood of survival. AC II and revised
BG are the current guidelines used to identify suspected LS cases. Briefly, they highlight
the family history of LS-associated cancer and diagnosis of LS-associated cancer under
the age of 50 years (AC and revised BG). Additionally, AC require exclusion of Familial
adenomatous polyposis (FAP) syndrome (Umar et al., 2004, Vasen et al., 1991). Revised
BG specify the situations in which tumors should be tested for MSI when LS is suspected
(Umar et al., 2004). In Finland, immunohistochemistry (IHC) is routinely performed on
all CRC and endometrial cancer cases. With IHC, the likely gene(s) for subsequent
mutational analysis can be identified (Kansikas et al., 2011, Yurgelun and Hampel,
2018). Additionally, MSI analysis is performed. Based on the IHC and MSI results,
mutation screening is performed. Reliable sequencing for mutations detection of PMS2
has proven demanding due to the 15 pseudogenes (Kasela et al., 2019).
5.2 Lynch-like syndrome (acquired condition mimicking Lynch
syndrome)
Besides germline mutations in MMR genes (LS), inactivation of the MMR pathway may
also be due to sporadic events: somatic methylation of the MLH1 promoter, or biallelic
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somatic changes such as somatic mutations or loss of heterozygosity (Geurts-Giele et
al., 2014, Mensenkamp et al., 2014). Colorectal carcinomas that are MMR-deficient in
the absence of MLH1 promoter methylation or germline mutations (LS) represent
Lynch-like syndrome (LLS) (Carethers, 2014). LLS patients typically fulfill AC II
(Vasen et al., 1991) or revised BG (Umar et al., 2004) but lack molecular diagnosis of
LS (germline mutations in MMR genes) (Carethers, 2014). However, not all LLS cases
show family history of colorectal cancer or the family history may be unknown.
Improved molecular mechanisms in diagnosis and tumor testing have made it possible
to identify LLS tumors in population-based cohorts. Only recently, Lynch-like syndrome
(LLS) was established as a consistent group of MMR-deficient tumors by identification
of double somatic mutations as the mechanism associated with the majority of the cases
(approximately up to 70%). The double somatic events lead to silencing of both alleles
of MMR gene enabling accumulation of replication errors in the genome (Geurts-Giele
et al., 2014, Haraldsdottir et al., 2014). The mechanisms behind the rest, and the somatic
and epigenetic profiles, are nevertheless, unknown. Earlier this year, Pearlman et al.
(Pearlman et al., 2019) proposed to differentiate colorectal cancer cases with identified
double somatic event from those cases with no obvious reason for MMR deficiency.
Comprehensive screenings for somatic mutations and epigenetic changes is expected to
gain crucial information on LLS tumor-specific characteristics. Originally, term ` Lynch-
like syndrome` was used collectively to all MMR-deficient cases fulfilling AC II and/or
revised BG with no obvious MMR germline mutation. In other words, out ruling the
possibility of LS was the only means of LLS diagnosis. Recently, a more specific term
“double somatic” has been suggested for cases in which the tumor is caused by two
simultaneous mutations in a single MMR gene causing the deficiency (Pearlman et al.,
2019).
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AIMS OF THE STUDY
Germline mutations in MMR genes are well established as the causative factor in Lynch
syndrome, but the somatic mutational and epigenetic profiles as well as the reasons
associated with organ selectivity in the MMR mutation carriers remain to be unsolved.
Only recently, LLS was classified as a separate group of MMR-deficient tumors by
identifying double somatic mutations as the mechanism associated with the majority of
the cases. The mechanisms behind the rest, and the somatic and epigenetic profiles, are
nevertheless, unknown.
The specific aims were:
1. To determine the somatic mutation profiles and epigenetic status of the LS
tumors of different organs, and to explore the interplay between genetic and
epigenetic changes in LS tumorigenesis
2. To evaluate the mechanisms associated with MMR deficiency in a hospital-
based cohort (patients operated in Jyväskylä Central hospital in 2000-2010), and
the incidence of LLS in Finland
3. To explore whether germline mutations in MMR genes play a role in breast
cancer tumorigenesis in LS mutation carriers
4. To investigate if LS synchronous ovarian and endometrial cancers have a shared
origin (primary tumor and a metastatic lesion) or represent individually
developing primary tumors
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MATERIALS AND METHODS
6. Patient samples (I-IV)
The material of studies I, III and IV consist of tumor (LS colorectal carcinomas and
adenomas, LS-CRCs and LS-ADs, LS ovarian carcinomas, LS-OCs, LS endometrium
carcinomas, LS-ECs) and their counterpart normal samples (and hyperplasia samples in
Study III) from individuals included in the National Lynch syndrome registry of Finland
(LSRFi) that currently consists of approximately 300 families and more than 1600 tested
LS carriers. In study III, we also identified all available breast carcinoma (BC) cases
from the tested mutation negative family members of patients registered in LSRFi (non-
carrier breast carcinomas, NC-BCs) that were collected as a control group. For the study
II, 762 consecutive colorectal carcinomas diagnosed during years 2000-2010 in the
Central hospital of Central Finland were collected. The number of tumors included in
each of the studies are summarized in Table 4 (see below 20.1. Patient characteristics:
germline mutations and ages at onset). Please see the original publications I-IV for more
information of the tumor characteristics. Our tumor and normal samples and patient
information collections are unique sets of research material collected from LSRFi,
relatives of patients registered to LSRFi, and from hospital region of Central Finland.
All tumor and hyperplasia samples and a proportion of normal samples (except for 31
blood samples in Study I) were formalin-fixed paraffin embedded (FFPE) tissue blocks
which were collected from the archives. The histology of the tumors and tumor
percentage of the FFPE samples was evaluated by a designated pathologist, and the
samples were cut into 10 mm sections with a microtome for DNA extraction accordingly.
Pathologist also evaluated a representative FFPE sample block and area in the tumor
block of which the corresponding normal sample was cut and further extracted, for
comparison.
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Data analyzed in the studies is generated solely for each of the studies, and will not be
reused in future studies. This novel data includes sequencing data, fragment analysis
data, text files, and images, and it is stored appropriately (see 19. Ethical issues). Any
data covered by copyright is not used. We require signed collaboration contracts with all
the collaborators to ensure open science practice.
7. DNA extraction
DNA was extracted according to non-enzymatic protocols described by Isola et al. for
FFPE samples (Isola et al., 1994) and Lahiri and Nurnberger for blood samples (Lahiri
and Nurnberger, 1991).
8. Protein expression by immunohistochemistry (IHC) (I-IV)
Protein expression status of the tumor specimens was analyzed using
immunohistochemistry (IHC) (Table 2). In studies I, II and IV, IHC was performed
using 4 μm thick whole-slide (and tissue microarray (TMA) in study II) FFPE tissue
sections, which were deparaffinized with xylene and dehydrated using graded alcohol.
Counterstaining with hematoxylin (Mayers HTX, Histolab) was conducted after antigen
retrieval, after which the tissue slides were cleared using xylene and mounted
appropriately. In study III, IHC analysis was conducted using 2 μm TMA sections from
FFPE blocks and following protocol: 15-minute incubation with 1mM EDTA/10mM
Tris/HCI buffer in which the pH was 9.0 at 99 OC. Designated pathologists in each study
reported their clinical findings of each sample.
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Table 2. Summary of methods
Method Study
Immunohistochemistry (IHC) I-IV
Microsatellite instability (MSI) analysis I-IV
Methylation-specific multiplex ligation-dependent
probe amplification (MS-MLPA) I-IV
4.5 Methylation-quantification of endonuclease-
resistant DNA (MethyQESD) analysis II
Exclusion of the Finnish founder mutation 1 II
Panel sequencing I-IV
Somatic mutation analysis I-IV
MMR second hit analysis I-III
Characterization of the most mutated genes I-III
In silico pathogenecity evaluation of somatic
mutations I
IonTorrent sequencing II
Mutation signature analysis III
Statistical analysis I-IV
8.1 MMR-proteins (I-IV)
Protein expression of each the four MMR genes was measured using IHC staining.
Undisputed nuclear staining in tumor cells demonstrates normal MLH1, MSH2, MHS6
and PMS2 expression, whereas negative immunostaining in cancer cells was interpreted
to indicate inactivation of the MMR gene in question, combined with the internal
positive control staining of the sample (blood vessels of stromal cells). The primary
antibodies used are listed in Table 3.
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Table 3. Summary of the primary antibodies used in IHC.
Study Antibody Clone Dilution
Incubation
time
Whole
slide
(WS)/
TMA Tumor tissue Manufacturer
I Anti-MLH1 ES05 1:50 60 min WS Colon
Daco North
America, USA
I Anti-MSH2
G219-
1129 1:1000 60 min WS Colon
BD
Pharmingen,
USA
I Anti-MSH6
EP49,
AC00-47 1:100 60 min WS Colon Epitomics, USA
I Anti-PMS2 EPR3947 1:1000 60 min WS Colon Abcam, UK
I, IV Anti-MLH1 G168-15 1:40 60 min WS
Ovary,
endometrium
BD
Biosciences/
Pharmingen,
Belgium
I, IV Anti-MSH2 FE11 1:60 60 min WS
Ovary,
endometrium
Calbiochem/
Oncogene
Research,
Germany
I, IV Anti-MSH6 44/MSH6 1:60 60 min WS
Ovary,
endometrium BD Biosciences
I, IV Anti-PMS2 A16-4 1:400 60 min WS
Ovary,
endometrium BD Biosciences
II Anti-MLH1
NCL-L-
MLH1 1:100 60 min TMA Colon
Novocastra,
Leica
Biosystems,
Germany
II Anti-MSH2 NA27 1:150 60 min TMA Colon
Oncogene
Research
Products, USA
II Anti-MSH6 287M-16 1:50 60 min TMA Colon
Cell Marque,
USA
II Anti-PMS2 556415 1:400 60 min TMA Colon
BD
Pharmingen,
USA
III Anti-MLH1 G168-15 1:60 60 min WS Breast BD Biosciences
III Anti-MSH2 FE11 1:80 60 min WS Breast
Oncogene
Research,
Germany
III Anti-MSH6 44/MSH6 1:40 60 min WS Breast BD Biosciences
IV
Anti-
L1CAM 1E11 1:40 20 min WS
Ovary,
endometrium Covance
IV
Anti-
ARID1A
HPA00545
6 1:200 20 min WS
Ovary,
endometrium
Sigma-Aldrich,
USA
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In study I, for visualization of MLH1, MSH2 and MSH6 antibodies, Ventana
BenchMark XT immunostainer with OptiView detection system was used, whereas
PMS2 was visualized using OptiView and Amplification detection system (Ventana
Medical Systems, Tucson, AZ, USA). In Study II, visualization was performed using
LabVision Autostainer 480 (Thermo Fisher Scientific, Fremont, CA, USA) and
BrightVision + polymer detection kit (ImmunoLogic BV, Duiven, The Netherlands). In
study III and IV, Dako EnVision+ (Dako, Glostrup, Denmark/Carpinteria, CA, USA)
reagents were used according to manufacturer’s protocol for visualization.
8.2 BRAF V600E (II)
BRAFV600E hotspot mutation status was determined using IHC staining, a validated
reliable method for BRAFV600E mutation detection (Thiel et al., 2013). Mutation specific
antibody (dilution 1:100, clone VE1, Spring Bioscience, Pleasonton, CA, USA) was
used for immunostaining. A 25-minute incubation with 1 mM EDTA/10 mM Tris/HCl
buffer with pH 8.0 at 99 OC was used for antigen retrieval. Positive staining was
interpreted as indication of BRAFV600E mutation whereas negative staining indicated
wild-type BRAF status (Thiel et al., 2013).
8.3 ARID1A and L1CAM (IV)
For antigen retrieval, PT-Module (Lab Vision, Ca, USA) was carried out at 98OC / 20
minutes in Evision TM Flex Target Retrieval solution. Solutions pH was 6.1 for
ARID1A and 9.0 for L1CAM (Agilent Technologies, USA). For ARID1A we used
rabbit produced antibody anti-ARID1A (20 minutes in dilution 1:200, HPA005456,
polyclonal, Lot D104841, Sigma-Aldrich, USA), and mouse produced antibody
Covance SIG-39110-200 for L1CAM (20 minutes in dilution 1:40, CD171, clone 1E11,
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Covance). Staining was performed using Autostainer 480 automated immunostainer
(Lab vision, CA, USA) and hematoxylin (Mayers HTX, Histolab) for counterstaining.
When the nuclei of tumor cells lacked staining but the stromal cells stained positive,
ARID1A expression was interpret as negative/abnormal. L1CAM expression was
interpreted as positive/abnormal when > 10% of tumor cells showed L1CAM expression.
9. Microsatellite instability (MSI) analysis (I-IV)
Microsatellite instability (MSI) status of the tumor specimens was analyzed using
polymerase chain reaction (PCR) and mononucleotide repeat markers BAT25 and
BAT26. These five markers are shown to be specific and sensitive indicators of MSI
status (Esemuede et al., 2010, Loukola et al., 2001). Tumors stable for both MSI-markers
were considered as microsatellite-stable (MSS), whereas tumors in which one or both
repeat markers were unstable were classified as microsatellite unstable (MSI). Samples
were classified as MSI-high when 2-5 of markers indicated MSI, MSI-low when only
one of the five markers indicated MSI, and MSS when none of the five markers indicated
MSI.
In study II, MSI analysis was conducted for part of the samples using IHC. Exhibition
of positive staining for all four MMR genes was considered as an indication of MSS
phenotype of the sample, whereas samples that exhibited undisputedly negative for one
or more marker genes were considered as MSI based on Shia et al. 2008 (Shia, 2008).
The tumors were considered MMR-deficient (dMMR) if the IHC staining was abnormal,
tumors exhibited MSI phenotype, or both. If both IHC staining was normal and tumor
showed MSS phenotype, tumor was classified as MMR-proficient (pMMR).
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10. Methylation analysis (I-IV)
The methylation data produced in the studies I-IV were primarily conducted using
methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)
method described by Nygren et al. (Nygren et al., 2005), except in study II, in which
Methylation-quantification of endonuclease-resistant DNA (MethyQESD) method was
the primary method used to define MLH1 methylation status. We used 200-600 ng of
DNA and followed the manufacturer’s instructions in all MS-MLPA analyses (MRC
Holland). Briefly, MS-MLPA analysis is based on probes containing recognition
sequence (GCGC) that is recognized by methylation-sensitive endonuclease HHaI
(Promega, Wisconsin, USA), which digests the GCGC site by binding to its
unmethylated CpG dinucleotide. Digestion can only occur if the CpG dinucleotides
within the restriction site are unmethylated because HhaI enzyme only recognizes
unmethylated CpG dinucleotides. When the C in the CpG dinucleotide is methylated,
sequences remain undigested and can be amplified generating a signal peak detectable
in PCR. After PCR, the products were separated by capillary electrophoresis using ABI
3730 Automatic DNA sequencer (Applied Biosystems, Carlsbad, CA, USA). The MS-
MLPA test produces a methylation dosage ratio (Dm), which varies between 0 and 1.0
illustrating the percentage of methylated DNA in the sample. Results were analyzed by
genotyping software GeneMapper versions 4.0 and 5.0 (applied Biosystems, Carlsbad,
CA, USA). For each tumor sample (and normal samples for comparison), the
methylation dosage ratio (Dm) was calculated according to Pavicic et al. (Pavicic et al.,
2011). The threshold for probe-specific hypermethylation in tumor tissues was
determined against normal DNA: mean methylation Dm in normal samples plus two
standard deviations. Conservative technical threshold for methylation detection was set
to Dm value 0.15, which corresponds to 15% of methylated DNA (Nygren et al., 2005),
and if the mean Dm plus two standard deviations was lower, Dm value 1.5 was used as
cut-off.
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10.1 CpG island methylator phenotype (I-III)
CpG island methylator phenotype (CIMP) phenotype is commonly used criteria in
colorectal carcinomas to indicate the methylation status of tumor suppressor genes.
Alternative 24 gene methylation panel was used for tumors originating from other tissues
(see 10.2 Methylation of 24 genes). We used commercial SALSA MS-MLPA
probemix ME042-B2 (MRC Holland, Amsterdam, The Netherlands) to study CIMP
status of the colorectal specimens. CIMP panel covers the CpG islands in promoter
regions of eight tumor suppressor genes CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1,
CDKN2A, CRABP1, and MLH1. CIMP probemix contains 3-5 probes per gene, and gene
was considered methylated when ≥25% of the probes were methylated (Berg et al.,
2014). Genes CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1 were under our
special interest as we followed the Weisenberger criteria in analyzing CIMP status
(Weisenberger et al., 2006), according to which the sample is considered CIMP positive
when at least three genes out of five (3/5) were methylated. Alternative Ogino panel
including all eight CIMP genes where minimum five out of eight genes methylated (5/8)
was used as comparison for CIMP criteria (Ogino et al., 2007).
As the CIMP panel also includes probes for MLH1 promoter region, it was also used to
determine the methylation status of MLH1 in studies I and II. Furthermore, the CIMP
panel includes a probe for sensitive and specific identification of BRAFV600E status, and
this was utilized in some samples in study II.
10.2 Methylation of 24 genes (I-IV)
As the CIMP phenotype is commonly used and solely validated for colorectal tumors
only, alternative methylation panel was used to define the methylator phenotype of
tumors from other origins. MS-MLPA and SALSA MS-MLPA probemix ME001-C1 (in
study III) and SALSA MS-MLPA probemix ME001-C2 (in study IV) (MRC Holland,
Amsterdam, Netherlands) covering 24 general tumor suppressor genes was used. These
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24 genes are methylated in several cancers, and specified in www.mrc-holland.com
(MRC Holland). The panel contains 1 probe per gene, except for RASSF1, for which the
panel contains two probes, and the gene was considered methylated if either of the two
were methylated. The Dm value was calculated and 0.15 threshold was used for
methylation, except for CDKN2B (in study IV, for which a Dm cut-off of 0.34 was set,
due to higher than expected values reported by MRC-Holland), as follows: mean Dm in
normal endometria was determined using LS normal endometrium samples, plus one
standard deviation. Based on our previous experience, threshold of five or more genes
methylated per sample was considered as hypermethylated, comparable to CIMP
positive phenotype (Joensuu et al., 2008).
10.3 Custom panel (IV)
A custom MS-MLPA panel was designed, according to manufacturer’s instructions, to
study the methylation status of genes RSK4, SPARC, PROM1, WT1-S, CABLES1,
HOXA10, and HOXA9, often methylated specifically in ovarian and endometrial cancer
(MRC Holland). This custom design panel included one probe for 7 genes supplemented
with SALSA MS-MLPA kit P-300-B1 human DNA reference-2 reagents. The Dm cut-
off value was individually calculated for each gene the way it was described for
CDKN2B gene above (see 10.2 Methylation of 24 genes).
10.4 MLH1 methylation status (II)
Colorectal samples with deficient MLH1 expression detected by IHC were further
studied for MLH1 promoter methylation in study II. Methylation-quantification of
endonuclease-resistant DNA (MethyQESD) was the primary method used. Quantitative
MethyQESD method combines methylation-sensitive digestion with realtime PCR as
described in (Bettstetter et al., 2008). Briefly, the methylation-sensitive endonuclease
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Hin6I only recognizes and cuts unmethylated CGCG sites, whereas methylated samples
remain uncut. This difference in proportions of methylated vs. unmethylated DNA can
then be determined by real-time PCR. Methylation threshold of 16.6% or more was used
as indication of methylation, as described (Bettstetter et al., 2008). Parallel MLH1
methylation analysis by MS-MLPA was conducted as MLH1 is included in the SALSA
MSMLPA probemix ME042-B2 (see 10.1 CpG island methylator phenotype). MS-
MLPA and other supportive data suggested, however, that some cases with methylation
percentage of ≥11.7% were considered as methylated.
11. Finnish founder mutation-specific test (II)
Majority of LS patients in Finland carry a 3.5 kb genomic deletion of exon 16 and its
flanking introns in MLH1. This specific mutation is called the ‘Finnish founder mutation’
due to its high incidence in the Finnish population. Due to the large size of the deleted
region, this mutation cannot be detected by standard sequencing. Therefore, a mutation
specific test was conducted for colorectal tumors with absent MLH1 expression using
IHC in study II, in order to exclude the mutation in this Finnish population-based
collection, as described by Nyström-Lahti et al. (Nystrom-Lahti et al., 1995).
12. Panel sequencing (I-IV)
Tumor and paired normal DNA samples were delivered to the Institute for Molecular
Medicine Finland (FIMM) for panel sequencing. We chose to target known cancer genes
by using the Nimblegen Comprehensive Cancer Panel (CCP) (Roche Diagnostics),
which is a 4 Mb design targeting 578 cancer-related genes and their intronic regions
compiled from the Sanger Institute Cancer Gene Census database (Sanger institute
Cancer Gene Census) and the NCBI Gene tests database (NCBI Gene tests database).
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ThruPLEX® DNA-seq Kit was used for library preparation and exon capture was
conducted according to manufacturer’s protocol (Rubicon Genomics), after which the
sequencing was performed on Illumina HiSeq 2500 platform (San Diego, CA, USA).
The variant calling pipeline (3.4 in study I and 3.6 in studies II-IV) is described in detail
by Sulonen et al. (Sulonen et al., 2011). Briefly, raw Illumina reads were merged with
SeqPrep, after which the resulting paired reads were trimmed of B blocks in the quality
scores from the end of the read, from which only reads of 36 or more base pair long reads
were selected for further processing. These reads were aligned against the human
genome GRCh37 reference-genome primary assembly using the Burrows-Wheeler
Aligner version 0.6.2 (Li and Durbin, 2009), and the alignment was refined using GATK
Indel Realignment version 3.4. After the alignment, reads mapping to multiple genomic
positions were removed, and potential PCR duplicates were removed using Picard
MarkDuplicates version 1. 90.
12.1 Somatic mutation analysis (I-III)
Somatic mutation analysis was performed by FIMM to identify mutations of somatic
origin using the data from panel sequencing of the tumor and paired normal samples.
Non-synonymous somatic mutations (missense, nonsense, frameshift, in-frame coding
deletion/insertion and splice site mutations) were selected for further analysis using
VarScan 2 mutation detection algorithm version 2.3.2 (Koboldt et al., 2012). High-
confidence somatic mutations were called using the following parameters: strand-filter
1, min-coverage-normal 8, mincoverage-tumor 6, somatic-p-value 1, normal-purity 1,
and min-var-freq 0.05. SnpEff version 4.0 (Cingolani et al., 2012) and Ensembl v68
annotation database (Yates et al., 2016) were used for mutation annotation. Misclassified
germline variants were filtered out by removing the common population variants
included in the Database of Single Nucleotide Polymorphisms (Database of Single
Nucleotide Polymorphisms (dbSNP), Build ID:130).
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Only variants with VarScan somatic p-value below 0.01 were considered as significant
and true, and only those were selected for subsequent analyses in studies I-IV. For this
reason, the term ` somatic mutation` is referred to any non-synonymous sequence change
with the possibility of being pathogenic (including traditional pathogenicity classes 3 -
5) throughout this book.
13. Ion Torrent sequencing (II)
Simultaneously with the panel sequencing conducted in FIMM, 15 of the colorectal
tumors in study II were sequenced with Ion Torrent in Central hospital of Central Finland
in Jyväskylä, Finland to verify the panel sequencing findings. MLH1, MSH2, MSH6 and
PMS2 coding and untranslated regions were covered by Ion Ampliseq™ (Thermo Fisher
Scientific) custom panel, which is designed for 125–175 bp amplicon range comprising
163 amplicons that covers 92.36% of the target areas. Standard manufacturer’s protocol
(Ion Ampliseq™) was used in library preparation, and sequencing was conducted using
Ion torrent PGM (Thermo Fisher Scientific). Torrent Suite™ Software (Thermo Fisher
Scientific) was used for primary data processing, and Ion reporter version 4.2 (Thermo
Fisher Scientific) for variant calling. Variants with less than 20× coverage were filtered
out.
14. MMR second hit analysis (I-III)
Second hit analysis was performed to identify the second, somatic mechanism leading
to MMR gene deficiency. Comprehensive Cancer panel (CCP) Sequencing data of MMR
genes was studied to identify possible somatic second hit point mutations, and the
promoter methylation of the MMR genes was studied by MS-MLPA in each sample.
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To identify the possibility of loss of heterozygosity (LOH) as a second hit, LOH analysis
was performed. When the primary mutation was a point mutation, VarSeq software
(GoldenHelix®) with VCP filtered panel sequencing data (.vcf-files) was used to
compare the data from tumor and their corresponding normal samples. The variant allele
reads (Alt) vs. reference allele reads (Ref) ratio was determined in both tumor (T) and
normal (N) DNA, and LOH ratio (R) calculated as follows: R = (Alt:Ref)T/(Alt:Ref)N.
The thresholds for LOH and putative LOH specified by Ollikainen et al. were used
(Ollikainen et al., 2005). When the primary mutation was a large deletion, MLPA
produced data (SALSA P003-C1 for MLH1 and MSH2 and SALSA 072-C1 for MSH6,
MRC Holland, Amsterdam, The Netherlands) was used in LOH analysis and the results
interpreted according to Zhang et al. (Zehir et al., 2017). Putative and strict LOH are
called LOH throughout this thesis.
15. In silico analysis of somatic mutations (I-III)
VarSeq (GoldenHelix®) was used for in silico evaluation of the somatic single
nucleotides variants (SNVs) in studies I, II, and IV. We used six individual algorithms
included in VarSeq to predict the effect of amino acid substitution on protein function:
SIFT (SIFT), PolyPhen-2 (Adzhubei et al., 2010), MutationTaster (Schwarz et al., 2014),
MutationAssessor (MutationAssessor), FATHMM (Shihab et al., 2013a, Shihab et al.,
2013b, Shihab et al., 2014), and FATHMM MKL Coding (FATHMM).
Pathogenicity classifications of MMR somatic mutations were done by checking against
the InSIGHT database (InSIGHT database (Leiden Open Variation Database, LOVD v.
2.0 Build 36) in studies I, II, and IV. Furthermore, somatic mutations in MMR genes and
somatic mutations in the top mutated genes (see 16. Identification of the top-mutated
genes, below) were also assessed against the Catalogue of somatic mutations in cancer
(Catalogue of somatic mutations in cancer (COSMIC)), and Human Splicing Finder
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(Human Splicing Finder) was used to predict the splicing consequences of SNVs in
splice site regions in the second hit analysis (see 14. MMR second hit analysis).
In study III, in silico predictions to assign a category of pathogenic significance of
somatic mutations in MMR genes were performed using Varsome-database (Varsome -
The Human Genomics Community).
16. Identification of the potential driver genes (top-genes) (I-III)
To identify the genes with the highest rate of mutations, the potential driver genes, we
developed a method used in studies I-III. First, the proportion of tumors in which a
particular gene was mutant was calculated for each of the 578 genes. Second, focusing
on high allele frequency mutations (frequency >25%) to increase the likelihood of clonal
(driver) as opposed to subclonal (passenger) mutations (Williams et al., 2016), and to
the distribution of mutated genes in LS colorectal tumors in Study I, a cut-off of 31%
was established to divide the tumors into groups of commonly and less commonly
mutated. This cut-off was subsequently applied to LS ovarian carcinomas in study I, LLS
tumors in study II, and breast carcinomas in Study III, to enable tumor type-specific
comparisons. Third, for each of the identified top-genes, a pathway annotation was
specified according to GeneCards (GeneCards, Human Gene Database) and relevant
publications from PubMed (PubMed). Finally, top-mutated genes were compared to the
list of 719 genes in Cancer Gene Census v85 (Cancer Gene Census).
17. Mutational signature analysis
Non-synonymous somatic mutations identified by the VarScan2 mutation detection
algorithm version 2.3.2 (see 12.1. Somatic mutation analysis) were selected to mutation
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signature analysis conducted by R package deconstructSigs (Rosenthal et al., 2016)
against the signatures recognized by the COSMIC database (Catalogue of somatic
mutations in cancer (COSMIC)). The following parameters were used: normal-purity 1,
strand-filter 1, min coverage 8 and 6 (for normal and tumour samples, respectively),
minimum variant frequency 0.05, and somatic p-value 1. The deconstructSigs applies
multiple linear regression model to the input data, thus, determining the individual
mutational profiles of the tumor samples. In the analysis, individual signatures of each
sample were combined with signatures of other tumors in each group (dMMR LS-BSc,
pMMR LS-BCs, NC-BCs, LS-CRCs, LS-OCs, and LLS-CRCs), and average of each
signature was calculated. Signatures with frequency lower than 5% were combined to
group ‘Other’. Validation of breast cancer signatures was conducted by identifying all
somatic high-confidence variants by Mutect2 (MuTect2) and analyzing the signatures
by MutationalPatterns R-package, according to Blokzijl et al (Blokzijl et al., 2018).
18. Statistical analyses
The statistical analyses presented in the studies I, II, and IV and in this thesis book were
performed using IBM SPSS Statistics software (IBM SPSS Inc., Chicago, IL, USA)
version 24 and version 25 in study III. The data’s applicability for parametric or non-
parametric tests was first tested. The statistical significance of mutations or mutated
genes’ distribution in independent groups was evaluated using the Mann-Withney U test.
The pairwise comparisons of frequency data was conducted by the Fisher’s exact test.
The Pearson correlation coefficient for parametric data was used to assess the
correlations. Two-tailed p-values < 0.05 determined the significant values.
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19. Ethical issues
Studies I-III are approved by the Institutional Review Board of the Helsinki University
Central Hospital (466/E6/01). In addition, study II is approved by the ethics committee
of Jyväskylä Central Hospital (Dnro 13U/2011). Study IV was approved by the
Institutional Review Boards of the Departments of Surgery (466/E6/01) and the
Obstetrics and Gynecology (040/95) of the Helsinki University Central Hospital
(Helsinki, Finland) and Jyväskylä Central Hospital (Jyväskylä, Finland) (Dnro 5/2007).
The National Supervisory Authority for Welfare and Health (Dnro 1272/04/044/07 and
Dnro 10741/06.01.03.01/2015) approved the use of the patient registry and collection of
archival specimens. Written consent forms were always obtained at the time of sample
collection.
Sensitive data is handled according to the EU’s general data protection regulations, and
it is never shared outside our research group. An important part of confidentiality
consists of handling the patient samples and clinicopathological information as unique
codes.
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RESULTS
20. Overview of the clinicopathological characteristics of the
patients and tumors (Studies I-IV)
20.1. Patient characteristics: germline mutations and ages at onset
The majority of Lynch syndrome patients carried germline mutations in MLH1,
accounting for 39/57 (68%) of the tumors. This reflected the prevalent Finnish founder
mutation I, a 3.5 kb genomic deletion of exon 16 and its flanking introns in MLH1.
Moreover, MSH2 and MSH6 germline mutations were identified in 9/57 (16%) carriers
each. (Table 4). None of the tumors were from germline mutation carriers of PMS2.
The mean age of onset was 44, 46, 58, and 49 years for LS-CRCs, LS-OCs, LS-BCs
(dMMR and pMMR combined), and LS-ECs, respectively. The mean age of onset for
all the LS tumors combined was 49 years. Among non-LS tumors studied, the mean age
of onset was 59 years for NC-BCs and 65 years in LLS-CRC, and 62 years combined
(Table 4).
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20.2 Comparison of somatic mutation counts and CIMP statuses between
tumor groups (Studies I-IV)
Panel sequencing of 578 cancer-relevant genes revealed the average number of 689
(172/Mb), 735 (184/Mb), and 414 (103/Mb) non-synonymous somatic mutations per LS-
CRCs, LS-OCs, and LS-BCs, respectively. When observing LS-BCs separately by their
MMR-status, an average of 696 (174/Mb) somatic mutations in dMMR vs. 131 (33/Mb)
in pMMR tumors were identified (p=0.015) (Table 4). Majority of LS tumors were
hypermutated: proportion of hypermutated tumors was 100% (18/18), 81% (13/16), 70%
(14/20), and 100% (3/3) in LS-CRCs, LS-OCs, LS-BCs (dMMR and pMMR combined),
and LS-ECs, respectively (Table 4).
The combined group of LS tumors (LS-CRC, LS-OC, and LS-BC both dMMR and
pMMR; n=54) revealed significantly more somatic mutations (average 611) compared
to breast carcinomas from non-carrier individuals (NC-BCs, n=10) (average 352 somatic
mutations, p=0.032) and LLS colorectal carcinomas (n=14) (average 124 somatic
mutations, p=0.027). Furthermore, the number of mutated genes out of the 578 CCP
panel genes was significantly higher in LS tumors combined (average 190 somatic
mutations), compared to NC-BCs (average 119, p=0.038) and borderline significant
compared to LLS-CRCs (average 82, p=0.050).
Hypermethylation (CIMP) was detected in 50% of LS-CRCs, 20% of LS-OCs, and 33%
of LS-ECs. No hypermethylation phenotype was observed in LS-BCs. Among non-LS
groups, hypermethylation phenotype was absent in NC-BC, but particularly frequent in
LLS-CRC (93%) (Table 4).
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20.3 Somatic mutation counts and CIMP statuses in Lynch-like syndrome
tumors (Study II)
In this thesis and in the study II, we refer to LLS when talking about tumors that are
MMR-deficient with no identified germline mutations in MMR genes or MLH1
promotor methylation. This includes tumors with identified double somatic changes in
MMR genes, tumors with only one identified somatic mutation in MMR genes, as well
as tumors in which no obvious causative mechanism could be identified in our study.
The average age of CRC onset in LLS patients was 65 years, which was significantly
higher compared to LS-CRCs (44 years, p=0.001), significantly lower compared to
CRCs with hypermethylated MLH1 (76 years, p=0.001), and lower than sporadic pMMR
CRCs from Study II (70 years, p=not significant).
Panel sequencing of LLS-CRCs identified an average of 124 (31/Mb) somatic mutations
per tumor, which was significantly lower compared to LS-CRCs (689, p<0,001) or all
studied LS-tumors combined (average 611, p=0.027) (Table 4).
Unlike the LS tumors, most LLS-CRCs proved to be CIMP positive (13/14, 93%)
without MLH1 promoter hypermethylation (Table 4). To the best of our knowledge, our
study was the first to report the association between LLS-CRCs and CIMP positive
phenotype.
20.4 Origin of synchronous Lynch syndrome ovarian and endometrial
tumors (Study IV)
The study of synchronous ovarian and endometrial carcinomas from LS-carriers was
conducted to resolve weather the tumors are individually arising primary tumors or
metastatic lesions of one tumor. The genetic and epigenetic characteristics of these
tumors indicate a shared origin, that is, the tumors are metastatic lesions of one primary
tumor in two locations. This result is concordant with sporadic synchronous ovarian and
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endometrial carcinomas that are also clonally related representing metastatic disease
(Anglesio et al., 2016, Schultheis et al., 2016).
All 13 synchronous carcinoma pairs were molecularly concordant based on MMR status,
ARID1A expression, L1CAM expression, and hypermethylation status for 7 and 24
genes (see Materials and Methods). Enough DNA material was available for targeted
sequencing of five tumor pairs, of which three pairs showed undoubtedly shared origin
with identical high confidence somatic mutations. A fourth tumor pair shared lower-
confidence somatic mutations (detected with relaxed criteria, accepting somatic p-value
<0.05), and was hence interpreted as of possibly shared origin. The fifth tumor pair only
shared a single somatic mutation with relaxed criteria, leaving the origin unsettled.
The complex endometrial hyperplasias and the endpoint lesion endometrial or ovarian
carcinomas exhibited high molecular concordance, suggesting convergence of the
ovarian and endometrial tumorigenic pathways associated with the metastatic disease.
20.5 Mechanisms of two-hit inactivation for MMR genes (Studies I-III)
In LS tumors (LS-CRCs, LS-OCs, and LS-BCs), where the germline MMR gene
mutation constitutes the first hit, somatic inactivation of the second allele of the deficient
MMR gene was investigated (Table 4), whereas in LLS-CRCs somatic inactivation of
both first and second allele was studied. The main mechanism of second hit in the
remaining active allele in LS-tumors was LOH (44%, 24/54). In 30% of the LS-tumors
(16/54) the second hit was a somatic point mutation. The second hit in the remaining
35% of LS-tumors remained to be discovered, partly due to insufficient DNA material
(Figure 5). By the techniques we used, the allele specificity could not be determined.
Results 53
Figure 5. First and second hit in LS tumor groups. Based on second hit analysis, LOH
was the main mechanism of the second hit in majority of LS tumors, and the main second
hit in all MMR-deficient tumors (LS CRC, LS ovarian carcinomas and LS dMMR breast
carcinomas). The second hit was more often detected in the dMMR tumor groups,
provided that enough material was available for the analysis (insufficient DNA material
was available in 5/16 of LS ovarian carcinomas).
Somatic MMR gene point mutation together with loss of heterozygosity provided the
major mechanism accounting for LLS-CRCs (Figure 6). Interestingly, double somatic
point mutations in MMR genes were identified in 3/10 (30%) of NC-BCs, although they
exhibited pMMR phenotype.
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Figure 6. First and second hits in LLS colorectal carcinomas and non-carrier breast
carcinomas. The first and second hit was identified in the majority of LLS CRCs (79%),
compatible with the tumors being MMR-deficient. In non-carrier breast carcinomas (all
MMR proficient), double somatic events in MMR genes were present in 30%.
21. Unique features for genetic and epigenetic profiles of
different tumors (Studies I-III)
21.1 Higher somatic mutation burden for hypermethylated tumors
(Studies I-IV)
MMR status was an important classifier of somatic mutation burden. When classifying
the tumors into MMR-deficient (dMMR, n=59) (LS-CRCs, LS-OCs, dMMR LS-BCs,
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and LLS-CRCs) and MMR proficient (pMMR, n=19) (pMMR LS-BCs and NC-BCs),
dMMR tumors had significantly more somatic mutations (average 569) compared to
pMMR tumors (average 247, p=0.004). Also, the number of genes mutated out of 578
genes was significantly higher in dMMR tumors (average 181 vs. 101, respectively,
p=0.004). LS-EC was not considered due to low number of samples.
Apart from the MMR status, tendency to acquire somatic mutations depended on the
presence vs. absence of a generalized hypermethylation phenotype (CIMP). When
observing the somatic mutational counts in all hypermethylated (n=25) and non-
hypermethylated (n=52) tumors (LS-CRC, LS-OC, LS-BC, NC-BC, and LLS-CRC), the
average somatic mutation counts and number of mutated genes (/578) were significantly
higher in hypermethylated tumors (702 vs. 378, p=0.046, and 207 vs. 143, p=0.034,
respectively). When considering only the LS tumors (hypermethylated n=12, non-
hypermethylated n=41), the difference was even more significant: average 1318 vs. 419
somatic mutations, p=0.00045, and 337 vs. 152 somatic mutations, p=0.00049,
respectively. Average numbers of somatic mutations in different tumor groups are shown
in Figure 7. The three endometrial carcinomas sequenced in study IV did not comply
with the general pattern since one that was hypermethylated had 132 somatic mutations,
whereas the two non-hypermethylated tumors had 72 and 1544 mutations.
Finally, a difference was observed between hypermethylated tumors from inherited vs.
acquired MMR gene mutation carriers: hypermethylated LS-CRCs (9/18) and LS-OCs
(3/16) had significantly more somatic mutations (843 and 2745, respectively) compared
to LLS-CRCs, of which 13/14 were hypermethylated (124, p<0.001 and p=0.003,
respectively).
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Figure 7. Average number of somatic mutations in hypermethylated and non-
hypermethylated tumor groups. Comparison of somatic mutational counts in tumors with
hypermethylation (red bars) and no hypermethylation (green bars) revealed more
somatic mutations in hypermethylated tumors. Significant difference was observed in
ovarian carcinomas (LS-OC) (p=0.017). Endometrial carcinomas are not presented in
the figure due to the low number of samples (n=3). Data concerning the BC samples is
from Lotsari et al. (Lotsari et al., 2012).
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21.2 Unique somatic mutation profiles for tumors from different organs
(Studies I-III)
Somatic mutation profiles of different LS tumors have remained poorly characterized.
Panel sequencing of 578 cancer related genes revealed that LS tumors bear unique
somatic mutation profiles. Genes harboring mutations with allele frequency of 25% or
higher in approximately 30% of tumors were regarded to be possible drivers. Among 49,
12, and 18 such “top mutated” genes identified for LS-CRCs, LS-OCs, and dMMR LS-
BCs, respectively, the most frequently mutated genes were KMT2D and NACA (61% of
LS-CRCs), KMT2C (63% of LS-OCs), and NACA (55% of dMMR LS-BCs) (Figure X
A – C (Figure 8). In pMMR LS-BCs, genes with mutations in only 22% of samples at
maximum were observed; hence, no driver genes meeting our selection criteria were
identified.
LLS-CRCs also had a unique set of top mutated genes compared to LS-CRCs (Figure 8
E). The most mutated gene was MAML2 that was mutated in 43% of the LLS tumors.
Only four out of 13 of the top genes were shared with LS-CRCs: PRKDC, TCF7L2,
ARID1A, and RPL22 were mutant in 33%, 28%, 44%, and 39% of LS-CRCs,
respectively. BCOR was among the top mutated genes of LLS-CRCs, and it was not
mutated with any of the LS-CRCs (p=0.028).
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22. Molecular classification of 762 colorectal carcinomas from a
population-based cohort (Study II)
In the stepwise study of population-based cohort of 762 CRCs, 655 pMMR (86%) and
107 dMMR (14%) CRCs were identified by immunohistochemical analysis of tumors
for MMR protein expression. The dMMR tumors were investigated further for MLH1
promoter methylation and germline mutations of MMR genes, resulting in 81 MLH1
hypermethylated (11%) and 9 LS cases (1%). The remaining 14 tumors (2%) with
neither MLH1 methylation nor LS germline mutations were classified as LLS tumors
(Figure 9). LS accounted for 8% and LLS 13% of dMMR CRCs.
Figure 9. Molecular classification of 762 colorectal carcinomas from a population-based
cohort. A step-wise characterization of 762 population-based colorectal carcinomas
identified that 86% of the tumors were MMR proficient (dark blue) and 14% MMR-
deficient (green), of which further analysis enabled identification of MLH1 promotor
hypermethylated (11%, orange), Lynch syndrome (1%, light green), and Lynch-like
syndrome (2%, yellow) tumors. Three tumors remained unclassified (<1%, light blue).
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23. Mutational signatures of LS tumors (Study III)
Mutation signature analysis in study III was performed to detect the individual signatures
of LS-BCs and compare them to the signatures of breast carcinomas from non-carrier
family members and LS tumors originating in other organs (Figures 10 and 11).
Signatures of individual samples were first analyzed. For each signature, average over
sample-specific values representing a specific tumor group was determined and used to
evaluate differences between the tumor groups. Signatures of dMMR LS-BCs resembled
other LS tumors more closely than signatures of NC-BCs. MMR deficiency-associated
signature 6 was present (frequency >5%) in all LS tumors but not in NC-BCs. Other
MMR deficiency associated signatures 20 and 26 were also found in dMMR LS-BCs,
LS-CRCs (only signature 26), and LS-OCs with >5% frequency (see details in Study
III). Notably, in addition to signature 6, pMMR LS-BCs also exhibited signature 20 with
frequency of 14%. NC-BCs also exhibited signatures 6 and 20 with low frequencies
<5%. When counting all the MMR deficiency associated signatures 6, 20, and 26
combined, NC-BCs had the lowest frequency (5%) and pMMR LS-BCs the highest
frequency (23%) (for comparison, the corresponding frequencies were 12% in dMMR
LS-BCs, 13% in LS-CRCs, and 16% in LS-OCs).
Results 65
Results66
Figure 11. Mutational signatures of different LS tumor groups. Mutational signatures of
LS tumor groups and non-carrier breast cancer group classified by their MMR-status.
Tumors with dMMR had more similar mutational signatures compared with signatures
of pMMR tumors. Signatures were calculated based on the averages of sample-specific
signatures in each group. Signature 26 in dMMR BS-BCs, LS-OCs, and LS-CRCs are
included in the red group ‘other’, as are all the other signatures with under 5% fraction.
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DISCUSSION
24. Differential diagnostics of Lynch syndrome
24.1 Sporadic dMMR MLH1 methylated CRC, LS CRC, and LLS CRC
Approximately 16% of all colorectal carcinomas show hypermutated phenotype, of
which majority also exhibit high-degree MSI, which is a consequence of MMR
deficiency (Cancer Genome Atlas, 2012). The majority, 80%, of MSI cases are sporadic,
in which the mechanism associated with MMR deficiency is biallelic MLH1 promoter
hypermethylation silencing the MLH1 gene (Boland and Goel, 2010, Lynch and de la
Chapelle, 2003). Often, positive CIMP status and BRAF V600E mutation coexist with
MLH1 hypermethylated sporadic CRC (Lynch et al., 2007). Approximately 11%
(81/762) of CRCs in our population-based study (Study II) showed MLH1
hypermethylation (Figure 9). Majority (76%) of them carried BRAF V600E mutation in
contrast to LS and LLS CRCs that were all negative for the mutation, and pMMR CRCs
that were 95% negative for the mutation. Unlike in MLH1 methylated CRCs, CIMP
positive status did not correlate with MLH1 hypermethylation in LS and LLS CRCs.
This thesis contributes to the increasing amount of information on MMR-deficient
colorectal cancers beyond Lynch syndrome. Approximately 12-15% of CRCs are caused
by deficiencies in MMR-machinery (Aaltonen et al., 1998, Moreira et al., 2012).
Inherited germline mutations in MMR genes (Lynch syndrome) account for up to 15%
of CRCs with deficient MMR expression or MSI phenotype, and 1-3% of unselected
colorectal cancers (Peltomäki, 2014).
Lynch-like syndrome (LLS) forms another group of MMR-deficient CRCs exhibiting
MSI phenotype (Carethers, 2014, Rodriguez-Soler et al., 2013). LLS tumors were
initially classified as dMMR tumors with no promoter hypermethylation of MLH1
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(Geurts-Giele et al., 2014, Haraldsdottir et al., 2014, Mensenkamp et al., 2014), and
therefore the only means to diagnose LLS was to exclude LS. Rodriguez-Soler et al.
were the first to classify MMR-deficient tumors with no germline mutations or promoter
methylation of MLH1 as LLS, suspecting that the causative MMR mutation was not
found due to methodological reasons or the complexity of the mutation. In other words,
LLS cases were assumed to be a heterogeneous group consisting of sporadic CRCs
combined with LS cases in which the suspected germline mutation in MMR genes could
not be identified (Rodriguez-Soler et al., 2013). They found that the standardized
incidence ratio of CRC was the lowest in families with pMMR or sporadic tumors (0.48),
and highest in LS families (6.04), whereas the incidence ratio for LLS families (2.12)
was in between, suggesting increased familial cancer risk in LLS.
Recently, another method for classification has been proposed. Pearlman et al. suggested
that since the incidence of double somatic mutations as the causative factor in many of
the LLS cases is now known, the tumors harboring biallelic somatic mutations
(pathogenic variant, PV) in MMR genes should be classified as double somatic (DS),
distinguishing them from the unclassified cases, in order to highlight the underlying
mechanism associated with MMR deficiency (Pearlman et al., 2019).
Our population-based study including 762 colorectal carcinomas identified 107 (14%)
dMMR cases, of which 81 (76%) were proven to be caused by MLH1 hypermethylation,
11 (10%) by double somatic events in MMR genes, and nine (8%) harbored germline
mutation in MMR genes (LS). Furthermore, three cases (3%) showed MMR deficiency
with no obvious reason to explain it, and three (3%) dMMR cases remained unclassified
due to inadequate analyses of MLH1 methylation or panel sequencing to determine the
status. In our study (Study II), DS and unexplained dMMR CRC cases were classified
as LLS (13%) (Figure 9). None of these LLS cases harbored BRAF V600E mutation
known to be associated with sporadic MSI tumors, consistent with previous studies
(Cohen et al., 2016, Xicola et al., 2019).
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Our results indicate that somatic MMR mutations together with loss of heterozygosity is
the major mechanism accounting for LLS tumorigenesis. Of the non-hypermethylated
dMMR tumors in our study, slightly higher proportion of DS cases were identified
(11/26, 42%) compared to the cohorts in Perlman et al. (33% and 31%), and slightly
lower proportion of LS cases (9/26, 35%) compared to the cohorts in Perlman et al. (58%
and 45%) (Pearlman et al., 2019). The limited size of our cohort (762 in total, 26 non-
hypermethylated dMMR CRCs) compared to the two cohorts in Perlman et al. (3346 in
total investigated, 232 non-hypermethylated dMMR CRCs; 1182 in total, 51 non-
hypermethylated dMMR CRCs) may likely cause this difference. Furthermore, we
considered all mutations that had the possibility of being pathogenic (not known to be
benign or likely benign) when observing somatic mutations in LLS cases, whereas
Pearlman et al. only considered pathogenic variants as possible hits (Pearlman et al.,
2019). Cohen et al. discovered significant increase in PIK3CA mutations in DS CRCs
(67%), and less in LS CRCs (22%), MLH1 hypermethylated (20%), and MSS (15%).
PIK3CA was among the top-mutated genes identified in our study (4/14, 29%), although
the difference was not significant compared to LS CRCs (1/18, 6% p=0.142).
The average age of CRC onset in our cohort was lowest in LS cases (44 years) compared
to LLS cases (65 years, p=0.001), and highest in patients with MLH1 hypermethylated
tumors (76 years, p=0.001 compared to LLS). Pearlman et al. also discovered
significantly higher age at diagnosis in LLS patients compared to LS patients: 59 (Ohio)
and 69 (Iceland) LLS (DS) vs. 52 (Ohio) and 62 (Iceland) LS (p<0.001), respectively,
but younger than estimated in sporadic tumors (Pearlman et al., 2019). Other studies
have reported similar ages at diagnosis for LS and LLS: median ages of 48 years in LS
vs. 53 years in LLS (Mas-Moya et al., 2015) and median ages of 49 years in LS vs. 55
years in LLS (Rodriguez-Soler et al., 2013), both significantly lower than median ages
reported for sporadic (MLH1 hypermethylated or mutant BRAF V600E) cancers (71 and
78 years, respectively).
Xicola et al. found a significant enrichment of mutations in DNA repair genes other than
MMR genes that could possible explain the mutator phenotype in LLS tumors (Xicola
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et al., 2019). There were 45 DNA repair genes in our panel including MMR genes. No
significant enrichment was discovered in our cohort when observing the “top-mutated”
genes required by our criteria, where a gene was required to be mutated in approximately
30% of the samples. Only PRKDC (36%) and MLH1 (29%) of the 45 DNA repair genes
were among the top mutated genes of LLS-CRCs, but they were frequently mutated in
other LS-tumors too: 35% and 17% in LS-CRCs, 19% and 13% in LS-OCs, and 36%
and 0% in dMMR LS-BCs, respectively.
Jansen et al. discovered that occasionally LLS (or suspected Lynch Syndrome, sLS) can
be explained by germline or somatic POLE/POLD1 variants together with consequent
somatic MMR mutations (Jansen et al., 2016). The targeted CCP panel, however, did
not include POLD1 or POLE genes and hence the mutation status of these genes in our
LLS tumor cohort remains unknown.
LLS and DS cases are relatively new categories awaiting comprehensive screening for
somatic mutations and epigenetic changes and comparison with LS tumors, such as we
performed, to gain more information on LLS tumor-specific characteristics.
Identification of their unique characteristics will enable improved diagnostics to separate
them from LS tumors, and development of targeted treatment specific to molecular
features of the tumors. Our finding of regular CIMP-positive phenotype (not affecting
promoter region of MLH1) and somatic mutational profiles characteristic for LLS CRCs
may facilitate diagnostics and guide the development of targeted treatments.
24.2 LS breast and ovarian cancer vs. BRCA1/2-associated and sporadic
cases
Breast and ovarian cancer share rare genetic mechanisms, such as mutations in BRCA1
and BRCA2, as well as environmental exposures associated with endogenous and
exogenous hormone exposures (Hulka, 1997). Furthermore, a recently published large
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genome-wide association study by Jiang et al. reported for the first time a significant
genetic correlation between breast and ovarian cancers (Jiang et al., 2019).
Tumor suppressor genes BRCA1 and BRCA2 are involved in homologous recombination
repair. They are the most common susceptibility genes for hereditary breast and ovarian
cancer with mutations causing predisposition to Hereditary Breast and Ovarian Cancer
Syndrome (HBOC) (Futreal et al., 1994, Wooster et al., 1995). Inherited predisposition
causes 5-10% of all breast cancers, and HBOC accounts for approximately 20-25% of
this predisposition (Futreal et al., 1994, Wooster et al., 1995). Majority (80%) of
pathogenic mutations in BRCA1 and BRCA2 are hereditary, that is, germline mutations
(Riaz et al., 2017). The cumulative lifetime risk in women carrying germline mutation
in either of these genes is significantly increased compared to general population: 65%
in BRCA1 and 45% in BRCA2 mutation carriers for breast cancer, occurring at a younger
age, and 39% in BRCA1 and 11% in BRCA2 mutation carriers for ovarian cancer (Juvet
and Natvig Norderhaug, 2008). It is important to diagnose the predisposing mutation
since mutations in BRCA1 and BRCA2 are highly penetrant and often associated with
aggressive forms of breast or ovarian cancer. A significant fraction of BRCA1 -associated
breast cancers do not express estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor (HER-2), and are hence considered as triple-
negative. In contrast, breast carcinomas from BRCA2 mutation carriers are rarely triple-
negative and hence resembled sporadic tumors in this respect (Atchley et al., 2008,
Mavaddat et al., 2012). BRCA1/2-associated ovarian cancer is typically of high-grade
serous histological type (McLaughlin et al., 2013), which also predominates among
sporadic ovarian carcinomas (Kurman and Shih Ie, 2008).
After HBOC, the second most common cause of hereditary ovarian cancers is Lynch
syndrome, accounting for approximately 2% of all ovarian cancers, and 8-13% of
hereditary ovarian cancers (Malander et al., 2006, Walsh et al., 2011). Unlike ovarian
carcinomas caused by HBOC, LS ovarian carcinomas generally represent well-
differentiated early stage tumors with mainly non-serous histology (Helder-Woolderink
et al., 2016).
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Studies published to date have contradictory results on whether breast cancer should be
regarded as a part of LS tumor spectrum (Aarnio et al., 1999, Buerki et al., 2012, Lotsari
et al., 2012, Pande et al., 2012, Saita et al., 2018, Watson et al., 2008, Win et al., 2012).
A large body of literature reporting molecular characterization of the LS breast tumors
and patients have yielded strong evidence that LS breast cancer should be considered as
LS-related cancer (Engel et al., 2012, Lotsari et al., 2012, Roberts et al., 2018, Saita et
al., 2018, Win et al., 2012). We have previously reported that breast carcinomas from
LS carriers resembles sporadic breast carcinoma in many clinicopathological respects,
but LS carcinomas with respect to genomic instability (Lotsari et al., 2012). In Study III
we discovered that dMMR LS-BCs exhibited mutational signatures comparable to
signatures in other LS-tumors and different from signatures from non-carrier BCs
(sporadic). Furthermore, both dMMR and pMMR LS-BCs showed signatures associated
with MMR-deficiency (Figure 11).
Multiple studies suggests that LS is caused by mutations primarily in MLH1 and MSH2
genes causing carriers to have the highest risk for colorectal, endometrial, and ovarian
cancers (Bonadona et al., 2011, Hampel et al., 2006, Hampel et al., 2008, Moller et al.,
2017a, Moreira et al., 2012, Palomaki et al., 2009). The cohorts in these studies,
however, often represent individuals with personal and/or family history of colorectal
and/or endometrial cancer, making the cohorts less ideal for the evaluation of the risk
for breast cancer in LS (Espenschied et al., 2017). Moreover, several studies have shown
that germline mutations in MSH6 and PMS2 are associated with breast cancer in LS
(Desmond et al., 2015, Espenschied et al., 2017, Minion et al., 2015, Roberts et al., 2018,
Tung et al., 2016). However, the study of Roberts et al. reporting 2-3 fold increased risk
for breast cancer in MSH6 and PMS2 germline carriers has been criticized for not
reporting the reason for which the genetic testing was originally conducted (Roberts et
al., 2018). Previous reports from the same research group indicate that more than half
would have been tested because of diagnosis of breast cancer, and the cohort would
therefore be misrepresentative. Recently, Dominguez-Valentin et al.  published a large
multicenter prospective study reporting the breast cancer risk to be comparable across
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all four MMR genes, with only a minor increase in the cumulative risk to ages 60 and
75 (7-8% and 12-15%, respectively) compared to the risk in general population
(Dominguez-Valentin et al., 2019). Other prospective studies have reported similar
results with no increased risk for breast cancer in LS mutation carriers compared to
general population (Moller et al., 2017a, Moller et al., 2017b, Moller et al., 2018). Our
cohort of breast cancers from LS mutation carriers harbored germline mutations in
MLH1 (11/20, 55%), MSH2 (4/20, 20%), and MSH6 (5/20, 25%). The reasons for large
proportion of MLH1 carriers and non-existent PMS2 carriers can be explained by the
Finnish founder mutation in MLH1 and by the rarity of PMS2 mutations in Finnish
population. Guidelines set by the National Comprehensive Cancer Network (NCCN)
state that solely the “suggestions” of increased breast cancer risk in LS patients are not
enough to endorse “increased screening above-average-risk breast cancer screening
recommendations” for LS carriers (Sorscher, 2019).
A study by Espenschied et al. (Espenschied et al., 2017) described that 27.3% (158/579)
of the MMR mutation carriers in their cohort did not meet any current criteria
(Amsterdam criteria or Bethesda guidelines) for LS testing. Furthermore, BRCA1/2 (and
not LS) testing criteria were significantly more likely met in MSH6 and PMS2 carriers
than in MLH1 and MSH2 carriers. They also reported that the available tumor MSI/IHC
results were discordant with the mutations in 12.5% of MHS6 and 18.2% PMS2 gene
associated cases, which complies with previous findings about lower IHC/MSI
sensitivity in MSH6 and PMS2 cases (Terdiman, 2005). Thus, MSH6- and PMS2-
associated cases are more likely to be missed by current LS testing (MSI/IHC), possibly
making them underrepresented in previous LS studies (Espenschied et al., 2017) as well
as in our studies.
While the average age of onset in BC was similar in LS-BCs (57 years) and NC-BCs (59
years) in our study, it was lower in dMMR LS-BCs compared to pMMR LS-BCs (53
years versus 63 years, p=0.036). This is higher than reported by Vasen et al. (46 years
on average) and Roberts et al. (50 years on average) (Roberts et al., 2018, Vasen et al.,
2001). The mean age of onset in LS-OCs in Studies I-III was 46 years, which is
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concordant with published reports (45 years), and up to 20 years younger than reported
in sporadic ovarian carcinomas (Helder-Woolderink et al., 2016).
Characterization of the molecular profiles of tumors is important for diagnosis and
treatment. The finding that metastatic MMR-deficient breast carcinomas responded
extremely well to immune checkpoint treatments, as reported by Kok et al. (Kok et al.,
2017), provides an illustrative example. Approximately half (55%) of the LS-BCs in
Study III were dMMR, which is concordant with previous studies (Win et al., 2013).
Based on the tissue of origin, MMR and MSI status may vary in LS carriers due to the
growth pattern of MMR deficient cells which is characterized by clonal heterogeneity
(Peltomäki, 2017). All the NC-BCs were pMMR, concordant with the reports stating
that sporadic dMMR breast cancers are extremely rare (Davies et al., 2017). The
molecular characteristics between LS-BCs and sporadic NC-BCs as well as between
dMMR and pMMR LS-BCs differentiated the groups from each other. In addition to the
mutational signatures, each BC group had their unique profiles of somatic mutations
(Figure 8).
The molecular profiles of synchronous endometrial and ovarian carcinomas (Study IV)
indicate shared origins of the tumors, that is, metastatic disease, consistent with
synchronous sporadic cases (Schultheis et al., 2016). However, conclusions of direction
of the metastasis cannot be made based on our data. Kelemen et al. discovered that
ovarian carcinomas synchronous with endometrial carcinoma highly resembled non-
synchronous endometrial carcinomas and to a lesser degree resembled non-synchronous
endometrioid ovarian carcinomas, implying metastasis from the endometrium to the
ovary (Kelemen et al., 2017). Another study suggests that endometrioid and clearcell
ovarian carcinomas have metastasized from endometrium (Karnezis et al., 2017). Our
data showed the strongest molecular resemblance between the synchronous ovarian and
endometrial carcinomas, and close molecular similarity between synchronous ovarian or
endometrial carcinomas and the non-synchronous cancers of the same tissue of origin.
However, endometrial hyperplasias were relatively frequent in patients with only
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ovarian carcinomas, which might indicate a continuum from endometrial precusors to
ovarian cancer.
25. Methods used in genetics and epigenetics
The past two decades have been extremely important in the field of human genetics. The
Human Genome Project conducted the first sequencing of the entire human genome in
2001 (International Human Genome Sequencing, 2004, Lander et al., 2001, Venter et
al., 2001). The sequencing method used in this project was traditional Sanger sequencing
which was extremely time-consuming and took approximately 15 years (Green et al.,
2015). In the following decade, commercial sequencing methods were developed
allowing the emergence of Next Generation Sequencing (NGS) methods that have
revolutionized cancer genetics. The ever-evolving and faster NGS methods have enabled
more cost effective sequencing of targeted regions, whole-exome, and whole-genome,
decreasing the costs from billions to thousands of dollars in just over two decades
(Morganti et al., 2019). Databases, such as The Genome Aggregation Database
(gnomAD) including 120 000 exomes and 15 000 whole genomes (Genome
Aggregation Database, gnomAD) are available for reference and control purposes.
NGS methods have enabled increasing and more detailed information on hereditary and
somatically acquired illnesses, such as cancer and many others. Based on this
information, more efficient diagnostic methods as well as targeted therapies have been
developed. Standard stratification of tumor mutation profiles and tailored management
of patients based on tumors mutational signatures is the future goal in oncological care
(Morganti et al., 2019).
The function of all genes in the human genome are not known, and with today’s
knowledge, the function of only a fraction of the entire genomic area is known.
Moreover, variant classification poses a challenge and the ‘interpretive gap’ leads to a
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large proportion of the variations in the genome being classified as ‘variants of unknown
significance’ (VUS) because their effect in gene function is unknown (Beroud et al.,
2016, Cutting, 2014). This raises a limitation to exome and whole-genome sequencing
results, because a lot of information with unknown significance is produced, as well as
lot of possibly significant information about other traits not associated to the original
disease. Is it necessary to produce all the data if it cannot be utilized or which could
possibly reveal information that has a significant impact on one’s health but is not
associated with the original condition that motivated the sequencing? Then again, the
information about human genome is constantly increasing, making it possible to
reinterpret the results in the future.
Large genomic deletions and insertions as well as copy-number variations (CNVs) are
known to occur in many cancers. NGS data may be used for detecting large genomic
rearrangements, such as CNVs (Schmidt et al., 2017). In studies I-IV, we used a mutation
specific test to identify the large deletion in MLH1 that is the Finnish founder mutation,
but other large deletions and insertions, complex rearrangements, as well as CNVs would
not have been reliably detected by the used panel testing method targeting the coding
regions. Deletions in EPCAM, secondarily inactivating MSH2 by hypermethylation
leading to MMR-deficiency (Kuiper et al., 2011) would likewise have been missed in
our studies. We also did not study changes in microRNAs (miRNAs), which are
important regulators of many cellular processes (Peng and Croce, 2016). miRNAs are
small non-coding RNAs that are associated with regulation of gene expression and have
been found to be highly dysregulated in cancer cells (Peng and Croce, 2016)
We chose to use a commercial gene panel covering 578 known cancer-related genes and
their intronic regions to limit the amount of information with unknown significance. To
identify true positive variants, somatic mutation analysis was conducted to detect the
non-synonymous somatic mutations. This, however, may affect for example the
mutational signature analysis since only non-synonymous variants in targeted regions of
the genome are covered, although reports that panel sequencing and/or restriction to non-
synonymous variations has been used to capture successful signatures do exist (Nowak
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et al., 2017, Zehir et al., 2017). There is a possibility that relevant mutations are located
in genes not included in the CCP-panel, which must be taken into consideration when
interpreting these results. Furthermore, majority or the LS-tumors in our data sets were
hypermutated limiting the effect of restriction to non-synonymous mutations. However,
all the samples in our studies were processed alike, so these limitations only concerns
comparisons to signatures reported by others. In the interest to detect clonal changes, we
focused mainly on somatic mutations with high allele frequency (≥ 25%); however, this
does not take into consideration the possibility of somatic mosaicism in which de novo
variants may exist in low frequencies (Renaux-Petel et al., 2018). Consequently, the
somatic mutations in MMR genes in study II would have been missed if they only
occurred in a small population of cancer cells. Published studies focusing on the somatic
mutation spectra of LS or LLS tumors are scarce, limiting the possibilities for
comparisons between investigations.
CIMP analysis with defined indicator markers is an established method to study the
methylation status of CRCs, but no established criteria exists for other tumor types.
Based on our previous studies (Niskakoski et al., 2013), the methylation status of tumors
other than CRCs was determined by methylation analysis of 24 tumor suppressor genes.
The methods to study the gene methylation have developed rapidly during the past two
decades, enabling genome-wide methylation analysis (Choukrallah et al., 2019). In the
studies I-IV, these genome-wide methods, however, were not utilized, in part because of
FFPE origin of our specimens. In the epigenetic studies, we only focused on the
promotor methylation analysis of CIMP panel genes, panel of 24 tumor suppressor
genes, and promoter methylation of MLH1 (the latter as the cause of deficient expression
of MLH1), and this limitation should be taken into consideration when interpreting the
methylation results.
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26. Future aspects
In the future, larger cohorts of samples preferably representing multiple populations
would be needed to verify our preliminary results on LS and LLS tumors. The epigenetic
changes together with hypermutability, and especially their cause and effect
relationships should be further studied. The predictive value of positive CIMP status
remains to be clarified in LLS patients, taken into consideration its association with
worse prognosis of colorectal cancer irrespective of MSI status. Furthermore, LLS
tumors potential response to PD-1 blockade-based immunotherapy should be studied, as
significantly better response has been observed in non-Lynch patients with MMR-
deficient tumors. Comparison with corresponding data derived from sporadic tumors
could also be relevant; for example, it would be interesting to study whether the
correlation we observed between CIMP/hypermethylated phenotype and high somatic
mutation burden also applies to sporadic tumors and which mechanisms are involved.
The molecular differences between dMMR and pMMR breast cancers, especially in LS
patients, should also be taken into consideration when considering the best treatments as
well as when new treatments are developed.
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SUMMARY AND CONCLUSIONS
NGS and epigenetic methods enable comprehensive characterization of somatic
mutations and methylation profiling of different tumors. Detailed characterization of LS
tumors from different tissues as well as LLS tumors bring important new information
that may be used for diagnosis and targeted treatment. Many of the somatically mutated
genes belong to signaling pathways to which targeted treatments exists or could be
developed.
Study I
· LS tumors harbored organ-specific profiles of somatic mutations
· Hypermethylated (CIMP positive) LS colorectal and ovarian tumors gained
more somatic mutations in cancer-relevant genes compared to non-
hypermethylated (CIMP negative) tumors
· Genes involved in epigenetic regulation were enriched among the top mutated
genes (potential driver genes)
· Signaling pathways such as DNA repair, Wnt, mTOR, PI3K, NOTCH, MAPK,
and tyrosine kinase were affected. These pathways may potentially be targeted
by for example pan-HER inhibitors in ERBB2-mutant MSI colorectal cancer
Study II
· LLS encompassed a significant proportion of MMR-deficient colorectal cancers
(17%), and most LLS tumors (11/14, 79%) were due to double somatic
mutations
· LLS colorectal carcinomas were found to be associated with CIMP-positive
phenotype, which has been associated with worse prognosis of colorectal cancer
irrespective of MSI status
· The profile of somatic mutations in LLS colorectal carcinomas differed from
that in LS colorectal carcinomas
· Frequent PIK3CA mutations may predict resistance to anti-EGFR therapy
Study III
· Approximately 50% of LS breast carcinomas were MMR-deficient, as a marked
distinction to sporadic breast carcinomas
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· MMR-deficient LS breast carcinomas showed mainly hypermutated phenotype
(91%), characteristic for other LS tumors, whereas MMR-proficient LS breast
carcinomas and breast carcinomas from non-carrier family members were
mainly non-hypermutated
· Mutational signatures of MMR-deficient breast carcinomas resembled the
signatures of other LS tumors (LS colorectal and ovarian) and differed from
breast carcinomas from non-carrier family members, but MMR-proficient LS
breast carcinomas, too, exhibited mutational signatures associated with MMR-
deficiency
Study IV
· Genetic and epigenetic characteristics of synchronous LS ovarian and
endometrial tumors indicated shared origin, that is, they are very likely a primary
tumor and its metastatic tumor
· Long term retrospective surveillance of female LS patients with endometrial
hyperplasias and endometrial and ovarian carcinomas as endpoint lesions
showed a high degree of genetic and epigenetic similarity between the
specimens. This suggested early convergence of ovarian and endometrial
tumorigenesis, which should be taken into account whenever ovarian or
endometrial lesions are observed
.
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